{"id":645829,"date":"2023-04-06T15:04:01","date_gmt":"2023-04-06T15:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=645829"},"modified":"2023-04-06T15:04:01","modified_gmt":"2023-04-06T15:04:01","slug":"nephrosclerosis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-states-delveinsight-key-companies-astellas-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nephrosclerosis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-states-delveinsight-key-companies-astellas-pharmaceuticals_645829.html","title":{"rendered":"Nephrosclerosis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Astellas Pharmaceuticals"},"content":{"rendered":"
\n
\"Nephrosclerosis<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Nephrosclerosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Nephrosclerosis, historical and forecasted epidemiology as well as the Nephrosclerosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n

DelveInsight’s “Nephrosclerosis Market Insights, Epidemiology, and Market Forecast-2032<\/a>“<\/strong> report delivers an in-depth understanding of the Nephrosclerosis, historical and forecasted epidemiology as well as the Nephrosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n

Nephrosclerosis Overview<\/strong><\/p>\n

The term hypertensive nephrosclerosis has traditionally been used to describe a clinical syndrome characterized by long-term essential hypertension, hypertensive retinopathy, left ventricular hypertrophy, minimal proteinuria, and progressive kidney failure. Most cases are diagnosed based solely on clinical findings. In fact, most of the literature dedicated to hypertensive nephrosclerosis is based on the assumption that progressive kidney failure in a patient with long-standing hypertension, moderate proteinuria, and no evidence suggesting an alternative diagnosis characterizes hypertensive nephrosclerosis.<\/p>\n

\"\"<\/p>\n

Nephrosclerosis Epidemiology Insights<\/strong><\/p>\n

The 50-59 and 60-69 age groups were the most affected. Men were predominant (51.8%), with an M \/ F sex ratio of 1.07. The majority of patients came from a rural area (67.9%). Three hundred and ninety-one patients (84.82%) were referred for impaired renal function. Hypertension was known in 435 patients (94.36%).<\/p>\n

Click here to learn more about the Nephrosclerosis Market Landscape<\/a><\/strong><\/p>\n

The Report Covers the Nephrosclerosis Epidemiology Segmented by:<\/strong><\/p>\n